Colovic, N. (6701607753)N. (6701607753)ColovicTomin, D. (6603497854)D. (6603497854)TominVidovic, A. (6701313789)A. (6701313789)VidovicTosic, N. (15729686900)N. (15729686900)TosicAtkinson, H.D. (7101883648)H.D. (7101883648)AtkinsonColovic, Milica D. (21639151700)Milica D. (21639151700)Colovic2025-06-122025-06-122012https://doi.org/10.1007/s12032-011-9834-yhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84864031957&doi=10.1007%2fs12032-011-9834-y&partnerID=40&md5=0884fe1c09e94de4ab2dfc5982e92a1ahttps://remedy.med.bg.ac.rs/handle/123456789/9702Central nervous system (CNS) involvement in acute promyelocytic leukemia (APL) is rare and tends to be seen mostly following treatment with all-trans retinoic acid (ATRA), due to prolonged patient survival and poor penetration of the drug in the CNS. At least 10% of extramedullary relapses in APL involve the CNS, and associated factors include an increased age, the BCR isoform, the development of differentiation syndrome, a high white cell count at presentation and hemorrhage into the CNS during induction therapy. We present the case of a patient with high-risk APL, CD56+, CD2+ in whom a CNS relapse was diagnosed through the presence of a PML/RARα rearrangement on PCR of the cerebrospinal fluid (CSF). © 2011 Springer Science+Business Media, LLC.